Bogus HIV tests
This article was originally published in The Gray Sheet
Executive Summary
Alfa Scientific Designs is charged by the Federal Trade Commission with falsely representing that its Alfa HIV-1/2 Rapid Tests accurately detect HIV in its third legal action to date against a marketer of HIV tests. San Diego-based Alfa supplied the faulty HIV tests to Medimax, Inc., which was charged by the FTC in December for falsely representing on the Internet that its HIV tests accurately detected the disease (1"The Gray Sheet" Dec. 6, p. 24). On Nov. 17, FTC announced a settlement of charges against Las Vegas-based Cyberlinx Marketing related to claims over the Internet that its tests accurately detected HIV, including a ban from marketing any HIV test kits and repayment of sales proceeds. Alfa has agreed to a stipulated preliminary injunction that will halt all sales of its HIV tests. The complaint and stipulated preliminary injunction were filed Jan. 13 in the U.S. District Court for the Southern District of California
You may also be interested in...
Bogus HIV tests
Federal Trade Commission charges David Rothbart, doing business as Medimax, Inc., with falsely representing on the Internet that his tests accurately detect HIV. At the request of the FTC, a federal district court in Orlando, Florida has issued a temporary restraining order against Rothbart. The agency's complaint seeks to permanently enjoin Rothbart and require payment of "consumer redress." Separately, Cyberlinx Marketing settled FTC charges earlier this month that the Internet company falsely represented its HIV home test kits as accurately detecting HIV. Under the stipulated final settlement order, Cyberlinx and its president, Jeffrey Stein, are banned from marketing HIV home test kits and must reimburse the money received from the sale of the kits
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.